Clinical Trials Browser

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT04469530 2026-02-27

AflacST1903

Phase 2 Recruiting

55 enrolled

Other solid neoplasm

Solid Tumor

NCT06942039 2026-02-27

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Phase EARLY_PHASE1 Recruiting

15 enrolled

CNS

Medulloblastoma, Neuroblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

232 enrolled

CNS

Ependymoma, Medulloblastoma, Recurrence

NCT01881048 2026-01-29

Window of Opportunity Study Targeting the Inflammatory Milieu

Phase EARLY_PHASE1 Completed

42 enrolled

Breast

Breast Neoplasms

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

39 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06076837 2026-01-12

The Seven Trial: Exploiting the Unfolded Protein Response

Phase 1 Active not recruiting

6 enrolled

Gastrointestinal

Pancreatic Cancer Metastatic

NCT03926338 2025-11-20

PICC

Phase 2 Recruiting

270 enrolled

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT07154316 2025-09-04

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Phase 2 Recruiting

138 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07150949 2025-09-02

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Phase 2 Recruiting

138 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02885974 2025-07-28

BLAST

Phase 1 Completed

22 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02432378 2025-06-19

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Phase 1/2 Terminated

25 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

PICC-3

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

FLUVABREX

NICHE

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

AflacST1502

AflacST1903

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

MEMMAT

Window of Opportunity Study Targeting the Inflammatory Milieu

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

The Seven Trial: Exploiting the Unfolded Protein Response

PICC

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Triple Negative Breast Cancer and Celecoxib. Pilot Study

BLAST

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines